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Abstract
Background: As an important cellular stress sensor phosphoprotein p53 can trigger cell cycle arrest and apoptosis
and regulate autophagy. The p53 activity mainly depends on its transactivating function, however, how p53 can
select one or another biological outcome is still a matter of profound studies. Our previous findings indicate that
switching cancer cells in high glucose (HG) impairs p53 apoptotic function and the transcription of target gene PUMA.
Methods and results: Here we report that, in response to drug adriamycin (ADR) in HG, p53 efficiently induced the
expression of DRAM (damage-regulated autophagy modulator), a p53 target gene and a stress-induced regulator of
autophagy. We found that ADR treatment of cancer cells in HG increased autophagy, as displayed by greater LC3II
accumulation and p62 degradation compared to ADR-treated cells in low glucose. The increased autophagy
in HG was in part dependent on p53-induced DRAM; indeed DRAM knockdown with specific siRNA reversed
the expression of the autophagic markers in HG. A similar outcome was achieved by inhibiting p53 transcriptional activity
with pifithrin-α. DRAM knockdown restored the ADR-induced cell death in HG to the levels obtained in low glucose. A
similar outcome was achieved by inhibition of autophagy with cloroquine (CQ) or with silencing of autophagy gene
ATG5. DRAM knockdown or inhibition of autophagy were both able to re-induce PUMA transcription in response to
ADR, underlining a reciprocal interplay between PUMA to DRAM to unbalance p53 apoptotic activity in HG. Xenograft
tumors transplanted in normoglycemic mice displayed growth delay after ADR treatment compared to those transplanted
in diabetics mice and such different in vivo response correlated with PUMA to DRAM gene expression.
Conclusions: Altogether, these findings suggest that in normal/high glucose condition a mutual unbalance between
p53-dependent apoptosis (PUMA) and autophagy (DRAM) gene occurred, modifying the ADR-induced cancer
cell death in HG both in vitro and in vivo.
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Background
In response to several types of genotoxic stress the p53
oncosuppressor is activated to control, as transcription
factor, genes regulating different cellular outcomes such
as cell-cycle arrest and apoptosis [1]. In this manner, p53
protects cells from genomic instability leading to
tumorigenesis, reduces tumor progression, and activates
the apoptotic response of tumor cells to anticancer
drugs [2]. Given its key role in restraining tumorigenesis
and tumor progression, p53 is frequently mutated in
over 50% of human cancer types and indirectly inacti-
vated in the other 50%, indicating that the presence of a
functional p53 pathway is incompatible with neoplastic
cell growth [3]. One of the most dramatic effects of p53
activation is the apoptotic clearance of cancer cells [4]
which is one of the two ideal goals of anticancer therapy,
the other being the stimulation of host tumor-specific
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response, both cooperating in the achievement of clinic-
ally relevant effects [5, 6]. Apoptotic signals can engage
two main pathways (the extrinsic and the intrinsic)
which are interconnected [7]. P53 is involved in both
pathways through the regulation of target genes that
encode, for instance, the mitochondrial BH3-domain
proteins NOXA and PUMA [8, 9]. PUMA (p53 upregu-
lated modulator of apoptosis) represents one of the most
potent pro-apoptotic BH3-only proteins and a key medi-
ator of p53-dependent apoptosis in response to a wide
variety of stress signals including genotoxic stress,
double- and single-stranded DNA breaks (i.e., UV, γ-IR,
purine analogues, topoisomerase inhibitors, chemothera-
peutic agents, etc.) but also oxidative stress, neurotoxins,
changes in microtubule structure, deficiency of growth
factors, hypoxia and viral infection [10]. The absence of
PUMA has been shown to cause high resistance of can-
cer cells to apoptosis induced by DNA-damaging agents,
such as adriamycin, 5-fluorouracil, cisplatin, etc. [11, 12].
Besides, p53 has been shown to play a critical role in
p53 in regulation of autophagy, a catabolic pathway by
which eukaryotic cells degrade and recycle macromole-
cules and organelles, particularly under conditions of
nutrient deprivation [13]. This may depend on p53 sub-
cellular localization and/or by p53 transcription-
dependent and -independent activities [14–16]. TP53
may induce autophagy through, for instance, activation
of AMPK kinase/mTOR signalling [17] or by transcrip-
tional induction of autophagy genes such as DRAM
(damage-regulated autophagy modulator), a lysosomal
protein and a stress-induced regulator of autophagy [18].
DRAM has been shown to be not only critical for the
ability of p53 to induce autophagy, but also for p53-
induced apoptotic cell death [19], contributing to the
complex mechanisms that regulate whether or not a cell
dies in response to p53. Thus, although p53 is involved
in the regulation of autophagy, the exact nature of this
link remains seemingly controversial [20].
Autophagy, along with apoptosis controls the turnover
of organelles, proteins and therefore the cell fate (sur-
vival/cell death). Generally autophagy blocks the induc-
tion of apoptosis that shuts off the autophagic process
and the dialogue between these two pathways influences
the normal clearance of dying cells [21]. Thus, autoph-
agy inhibits apoptosis in mammalian cells [22] and facili-
tates the resistance of tumor cells to anticancer agents
[23]. Therefore, knowing the mechanisms that rule the
interplay between these two cellular processes (autoph-
agy/apoptosis) has important pathophysiological conse-
quences [24]. Recently we reported that high glucose
(HG) condition reduces the tumor cell response to drug-
induced apoptosis due to impairment of p53 apoptotic
function. Mechanistically we found that HG induces
homeodomain-interacting protein kinase 2 (HIPK2)
protein degradation leading to impairment of HIPK2/
p53 apoptotic axis with inhibition of p53 apoptotic tar-
gets PUMA and p53AIP1 [25, 26].
In this study, we present evidence that HG condi-
tion changes the p53 transcriptional activity from
PUMA to DRAM with the consequence of impair-
ment of drug-induced cell death. We also show that
p53-induced DRAM sustains HG-triggered autophagy
and that either DRAM or autophagy inhibition re-
store both PUMA transcription and drug-induced cell
death in vitro and in vivo.
Methods
Cell culture and reagents
In this study colon cancer RKO, HCT116, and HCT116-
p53−/− cells were used. Cells were routinely cultured in
DMEM (Dulbecco’s Modified Eagle’s medium) (Life
Technology-Invitrogen, Eggenstein, Germany) contain-
ing 1 g/L D-glucose (low glucose - LG), supplemented
with 10% heat-inactivated fetal bovine serum (FBS) plus
100 units/ml penicillin/streptomycin, and glutamine, in
5% CO2 humidified incubator at 37 °C. For high glucose
(HG) condition, low glucose culture medium was re-
placed with DMEM containing 4.5 g/L D-glucose (Life
Technology-Invitrogen) supplemented with 2% FBS for
24 h, as previously reported [25–28], before performing
other treatments for the indicated times.
To generate a cell line stably expressing GFP-LC3,
3 × 105 RKO cells were cultured into 6-well plates and
transfected with 5 μg of pEGFP-LC3 expression vector
(kindly provided by Moshe Oren, Weizmann Institute
of Science, Rehovot, Israel) with Lipofectamine Plus
(Invitrogen, Monza, Italy) according to the manufac-
turer’s instructions. Forty-eight hours after transfec-
tion cells underwent selection with geneticin G418
(1.5 mg/ml). After 10–14 days, the selected GFP-LC3-
positive clones were visualized on a Nikon Eclipse Ti-U
fluorescence microscope (Nikon).
Chemotherapeutic drug Adriamycin (ADR) (Sigma)
was added in culture medium at 2 μg/ml for 16–24 h;
the inhibitor of autophagic protein degradation chloro-
quine (CQ) [29] (Sigma-Aldrich) was added in culture
medium at 25 μM for 16 h; p53 inhibitor pifithryn-α
(PFT-α) [30] (ENZO Life Sciences, Lausen Switzerland)
was used at 30 μM for 16–24 h, as reported [31].
Viability assay
For viability assay, subconfluent cells were plated in du-
plicate in 60 mm multiwell Petri dishes and 24 h later
culture medium was replaced with HG or low glucose
medium, both containing 2% FBS. The day after, ADR (2
μg/ml) were added to cell cultures for 16–24 h. Both
floating and adherent cells were collected and cell viability
was determined by Trypan blue (Sigma, St. Louis, MO,
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USA) exclusion by direct counting with a haemocytom-
eter. The percentage of cell death, as blue/total cells, was
assayed by scoring about 200 cells per well in triplicate.
Cell death/PI staining
Cell death was quantified by Fluorescence Activated Cell
Sorting (FACS) analysis, staining cells with the nonvital
dye propidium iodide (PI) (Immunological Sciences,
Rome, Italy), following the manufacturer’s instruction
[32]. Briefly, floating cells were collected by centrifuga-
tion and pooled with adherent cells recovered from the
plates, fixed in 80% ethanol and stained in a PBS solu-
tion containing PI (62.5 mg/ml; Sigma-Aldrich), and
RNase A (1.125 mg/ml; Sigma-Aldrich). Samples were
acquired with a FACScan instrument (Becton Dickinson
Europe Holdings SAS - Le Pont De Claix, France) and
the percentage of cells in sub-G1 compartment was cal-
culated using ModFit LT software (Becton Dickinson).
About 30.000 events were acquired and gated using for-
ward scatter and side scatter to exclude cell debris.
Western blot analysis
Total cell extracts were prepared by incubation in lysis
buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM
EDTA, pH 8.0, 150 mM KCl, 1 mM dithiothreitol, 1%
Nonidet P-40) and a mix of protease and phosphatase
inhibitors (Sigma-Aldrich). Protein concentration was
then determined using BCA Protein Assay kit (Bio-Rad,
Hercules, CA, USA). Samples were then denatured in
SDS sample buffer. Total proteins were separated by
loading 20–60 μg of total cell lysates on denaturing 6–
20% SDS-PAGE (Bio-Rad) and transferred to polyvinyli-
dene difluoride (PVDF) (Merck Millipore, Billerica, MA,
USA) or nitrocellulose (Bio-Rad) membranes. Unspecific
binding sites were blocked by incubating membranes for
1 h in 0.05% Tween-20 (v/v in TBS) supplemented with
5% non-fat powdered milk or bovine serum albumin,
followed by overnight incubation with the following
primary antibodies: rabbit polyclonal anti-LC3B (Sigma-
Aldrich), mouse monoclonal anti-p62 (SQSTM1, D-3)
(Santa Cruz Biotechnology, Dallas, TX, USA); mouse
monoclonal anti-poly(ADP-ribose) polymerase (PARP,
cleavage site-214/215, Millipore); and mouse monoclonal
anti-β-actin (Calbiochem, San Diego, CA, USA). Primary
antibodies were detected with appropriate anti-
immunoglobulin-G-horseradish peroxidase secondary
antibodies (Bio-Rad). Enzymatic signals were visualized
using chemiluminescence (ECL Detection system,
Amersham GE Healthcare, Milan, Italy). Images were
acquired with the EPSON Expression 10,000 XL scan-
ner (Epson, Long Beach, CA, USA) and densitometry
was performed with the ImageJ software (NIH, Bethesda,
MD, USA).
RNA extraction and semi-quantitative reverse transcription
(RT)-PCR analysis
Cells were harvested in TRIzol Reagent (Life Technology-
Invitrogen) and total RNA was isolated following the man-
ufacturer’s instructions, as previously reported [25]. The
first strand cDNA was synthesized from 2 μg of total RNA
with MuLV reverse transcriptase kit (Applied Biosystems,
Foster City, CA, USA). Semi-quantitative Reverse-
Transcribed (RT)-PCR was carried out by using Hot-
Master Taq polymerase (Eppendorf, Milam Italy) with 2 μl
cDNA reaction and genes specific oligonucleotides under
conditions of linear amplification. PCR products were run
on a 2% agarose gel and visualized with ethidium bromide.
The housekeeping 28S gene, used as internal standard,
was amplified from the same cDNA reaction mixture.
Densitometric analysis was applied to quantify mRNA
levels compared to control gene expression.
siRNA interference
Cells were plated at semiconfluence in 35-mm Petri
dishes the day before transfection. Control-siRNA,
siDRAM (sc-96,209; Santa Cruz) and siATG5 (Dharmacon,
Thermo Scientific, Milan, Italy) were transfected over-
night using Lipofectamine Plus reagent (Invitrogen).
DRAM silencing was evaluated 48 h after transfection
by RT-PCR analysis.
In vivo tumor growth
In vivo experiment was performed by using six-week-old
CD-1 male nude (nu/nu) mice (Charles River Laborator-
ies). They were housed in specific pathogen-free condi-
tions and fed standard cow pellets and water ad libitum.
Studies were performed in accordance with the National
Cancer Institute Regina Elena standard guidelines for
animal care; all experimental protocol were approved by
the Ethical Committee for animal research of the
National Cancer Institute Regina Elena in Rome, Italy,
and by the Italian Ministry of Health, and performed in
accordance with the Italian and European legislation.
For diabetes induction the mice were injected intraperi-
toneally with a single high dose of 160 to 240 mg/kg
streptozotocin (STZ) (Sigma-Aldrich) which is consid-
ered to achieve consistently a diabetic state with limited
morbidity and mortality [33]. The mice were subse-
quently hydrated with 1.0 ml normal physiologic saline
administrated subcutaneously. Blood was obtained by
lancet prick in the tail. Blood glucose concentration was
monitored once before and daily after STZ injection
until a diabetic state was confirmed by the glucose de-
hydrogenase method. After mice reached a glucose con-
centration exceeding 300 mg/dl (considered diabetic),
solid tumors were obtained by injecting i.m. on the flank
of each mouse 4 × 106 viable RKO cells suspended in
0.1 ml PBS. The mice were examined every day after
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injection until tumors reached approximately 300 mm3
volume (about 7 days from injection). Mice were then
randomized in four groups (6–8 mice/group) and
injected with ADR (10 mg/kg body weight) i.p or PBS as
control, as follow: 1) normoglycemic/PBS (Mock), 2)
normoglycemic/ADR, 3) diabetic/PBS, 4) diabetic/ADR.
Tumor dimensions were measured every other day and
their volumes were calculated from caliper measure-
ments of two orthogonal diameters (x and y, larger and
smaller diameters, respectively) by using the formula,
volume = xy2/2. When the ADR effect on tumor growth
delay reached statistical significance between normogly-
cemic and diabetic groups, tumors were harvested and
RNA extracted for analysis of PUMA and DRAM ex-
pression by RT-PCR.
Statistical analysis
Each experiment, unless differently specified, was per-
formed at least three times. Results are expressed as
values of mean ± S.D. Statistical significance was deter-
mined using Student’s t-tests for two sample compari-
sons and one-way ANOVA analysis for three or more
sample comparisons.
Results
High glucose (HG) switched the adriamycin (ADR)-induced
p53 transcriptional activity from PUMA to DRAM
We first evaluated whether the glucose amount influ-
enced the p53 transcriptional activity in response to
drug. To this aim, HCT116 and RKO cells were cultured
in low glucose (LG) and high glucose (HG) media and
treated with adriamycin (ADR). The results of RT-PCR
analyses of mRNA levels show that PUMA was greatly
induced by ADR in LG, as expected [25], while was not
induced in HG (Fig. 1a); on the contrary and opposite to
PUMA, DRAM was specifically induced by ADR in HG
while was not induced in LG (Fig. 1a). To assess if
DRAM was specifically induced by p53 in this setting, as
it can be also activated by p73 a p53 family protein [34],
we inhibited p53 transcriptional activity with pifithrin-α
(PFT-α) [30]. We found that the expression of DRAM,
induced by ADR in HG, was efficiently impaired by
PFT-α co-treatment (Fig. 1b). Similarly, neither DRAM
nor PUMA were induced in HCT116-p53−/− treated
with ADR in, respectively, LG and HG (Fig. 1c), demon-
strating that both genes were induced by p53 in different
glucose culture condition.
HG culture condition increased autophagy in ADR-treated
cells in part depending on p53 activity
To evaluate the occurrence of autophagy, RKO cells
were stably transfected with GFP-LC3 plasmid and se-
lected as mixed population. Then, cells were cultured in
LG and HG media and treated with ADR. Autophagy
induction was evaluated by the appearance of GFP-LC3
puncta, indicating autophagosome formation, The cells
displaying more than 5 dots/cell were considered under-
going autophagy, and the measurements were performed
in the presence of autophagy inhibitor choroquine (CQ),
an inhibitor of the lysosomal function and therefore indica-
tive of autophagic flux, as reported [29, 35]. We found that
the LC3 puncta formation in cells cultured in HG was
slightly increased compared to cells cultured in LG and that
ADR treatment further increased the LC3 puncta formation
in HG compared to the same treatment in LG (Fig. 2a, b).
Next Western blot analysis of the expression of LC3
(microtubule-associated protein light chain 3) after conver-
sion from LC3-I to its autophagosome membrane-
associated lipidated, activated LC3-II form was performed,
in the presence and in the absence of CQ. We found that
LC3-II conversion, following ADR treatment in LG
Fig. 1 High glucose (HG) switched the adriamycin (ADR)-induced p53
transcriptional activity from PUMA to DRAM. (a) RKO and HCT116 cells
were kept in low glucose (LG) or high glucose (HG) medium for 24 h
and then treated with ADR (2 μg/ml) for 16 h before being assayed for
semi-quantitative RT-PCR analysis of PUMA and DRAM gene expression.
28S was used as a control for efficiency of RNA extraction and
transcription. Histograms representing quantification of PUMA or
DRAM/28S ratio as assessed by densitometric analysis are shown.
Densitometric values were quantified using the ImageJ software
and normalized to control. The values of control were set to 1.
The data are presented as means ± S.D. of three independent
experiments. *P < 0.001. (b) RKO and HCT116 cells were treated
with ADR (2 μg/ml) for 16 h in LG and HG medium, with or without
p53 inhibitor pifithrin-α (PFT-α) (30 μM) before being assayed for semi-
quantitative RT-PCR analysis of PUMA and DRAM gene expression. 28S
was used as a control for efficiency of RNA extraction and transcription.
One representative experiment is shown. (c) HCT116-p53−/− cells were
treated and assayed as in (a)
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medium, was greatly increased by HG medium (Fig. 2c, d),
suggesting increase of autophagy in HG. We then evaluated
whether p53 was involved in autophagy increase. To this
aim, p53 transcriptional activity was inhibited by using
PFT-α. As shown in Fig. 3a, the LC3-II conversion follow-
ing ADR treatment in HG medium was impaired by PFTα
co-treatment. Analysis of p62, a bona fide autophagic sub-
strate [35], showed that the reduced levels following ADR
treatment in HG were counteracted by PFTα co-treatment
(Fig. 3a). The role of DRAM was then assessed by using
siRNA interference (Fig. 3b). As shown in Fig. 3c, the deg-
radation of p62 in ADR/HG condition was impaired by
DRAM interference. Altogether these findings suggest that
HG condition increased the ADR-induced autophagy and
that such outcome was in part depending on p53 activity
and DRAM expression.
Autophagy inhibition or DRAM silencing restored ADR-
mediated cell death in HG
Next, we evaluated whether autophagy was involved in
reduction of drug-induced cell death in HG. To this
purpose cells were treated with ADR in LG and HG, in
the presence or absence of autophagy inhibitor CQ. The
results show that the ADR-induced cell death in LG, as
assessed by PI staining and FACS analysis, was signifi-
cantly reduced in HG condition; interestingly, blocking
autophagy with CQ rescued the ADR-induced cell death
in HG approximately to the levels obtained in LG
(Fig. 4a, upper panel). CQ alone did not induce cell
death (data not shown). In agreement, Western blot ana-
lysis show that the expression of the apoptosis marker
(cleaved) PARP in response to ADR in LG was reduced
by HG and rescued by CQ co-treatment (Fig. 4a, lower
panel). To further evaluate the role of autophagy, deple-
tion of ATG5, one of the members of the ATG family
necessary for autophagy because of its role in autopha-
gosome elongation [36], was performed with specific
siRNA. We found that ATG5 knockdown rescued the
cell death inhibited in ADR/HG condition to almost the
levels obtained by ADR in LG (Fig. 4b). Next the role of
DRAM was assessed in both RKO and HCT116 cells.
The results show that the ADR-induced cell death in LG
Fig. 2 HG increased autophagy in ADR-treated cells. (a) RKO stably transfected with GFP-LC3 plasmid were kept in low glucose (LG) or high glucose
(HG) medium for 24 h and then treated with ADR (2 μg/ml) for 16, in the presence or absence of autophagy inhibitor chloroquine (CQ, 25 μM) for 4 h
before observation to count GFP-LC3 puncta under fluorescence microscopy. Green indicates GFP-LC3. One of 10 representative micrographs is shown.
(b) The relative number of GFP-LC3-positive cells was calculated from 10 random fields. The data are presented as the means ± S.D. from three
independent experiments. (c) RKO cells were kept in low glucose (LG) or high glucose (HG) medium for 24 h and then treated with ADR
(2 μg/ml) for 16 h in the presence or absence of 25 μM chloroquine (CQ), and the expression of LC3-I/II was measured by western blot
analysis. One representative experiment is shown. β-actin was used as internal control. (d) Findings as in (c) were assessed by quantitative
analysis of LC3II-I/β-actin protein levels and shown as histograms. The data are presented as the means ± S.D. from three independent
experiments. *P < 0.001
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and significantly reduced by ADR treatment in HG con-
dition, was mostly restored by silencing DRAM with
siRNA (Fig. 4c). Altogether, these data suggest that au-
tophagy and/or DRAM expression were responsible, at
least in part, of reduced cancer cell death in response to
ADR in HG condition.
Autophagy inhibition or DRAM silencing restored ADR-
mediated PUMA transcription in HG
Next we evaluated whether blocking autophagy and/or
DRAM could influence PUMA transcription in HG. RT-
PCR analyses of mRNA levels in RKO and HCT116 cells
show that PUMA expression was induced by ADR in LG
while was not induced in HG (Fig. 5a, compare lane 2
with lane 6), as expected; interestingly, PUMA was in-
duced by ADR in HG only in the presence of CQ (Fig. 5a,
compare lane 6 with lane 7), while the ADR-induced
PUMA expression in LG was not further increased by CQ
co-treatment (Fig. 5a, compare lane 2 with lane 3). As
opposite to PUMA, DRAM expression was induced by
ADR only in HG, as seen above, but inhibited by CQ
co-treatment (data not shown). Interestingly, PUMA was
induced by ADR in HG following siRNA silencing of
DRAM (Fig. 5b, compare lane 4 with lane 6), as assessed
by densitometric analysis (Fig. 5c). Altogether, these find-
ings suggest that the p53 pro-apoptotic function, impaired
in HG, could be restored by autophagy inhibition or
DRAM depletion. Therefore, we hypothesize that, down-
stream of p53, autophagy might sustain inhibition of p53
pro-apoptotic function in a regulatory loop.
Diabetes reduced the effect of chemotherapy that correlated
with increased DRAM and reduced PUMA gene expression,
in vivo
Finally, the biological effect of the hyperglicemic micro-
environment on drug response was evaluated in a nude
mouse model of Streptozotocin (STZ)-induced diabetes
[33], to recapitulate the in vitro results. After the mice
achieved a consistent diabetic state, as evaluated by
blood glucose concentration exceeding 300 mg/dL, com-
pared to the normal group that maintained blood
glucose concentration around 100 mg/dL (Fig. 6a), we
generated tumor xenografts by injecting RKO cells, as
previously reported [37, 38], in both diabetic and
normoglycemic groups. Cells were implanted into nude
mice by i.m. injection and allowed to develop into palp-
able tumor nodules (about 300 mm3) at the injection
sites. The mice were then treated with ADR and tumor
volumes were calculated from caliper measurements.
Ten days after injection only normoglycemic mice
treated with ADR displayed significant tumor growth
delay (ADR versus Mock: *P < 0.001), compared to the
same treatment in diabetic (SZT) mice (Fig. 6b). Then,
tumors were harvested and mRNA extracted for p53 tar-
get gene expression by RT-PCR analyses. The results
show that PUMA was significantly induced by ADR
treatment in normoglycemic mice (Fig. 6c) while weakly
induced in SZT mice; on the contrary, DRAM was in-
duced by ADR treatment in diabetic mice while was not
induced in normoglycemic ones, in agreement with the
above in vitro data. This experiment recapitulated the in
Fig. 3 Increase of autophagy of ADR-treated cells in HG was in part depended on p53 activity. (a) HCT116 cells were treated with ADR (2 μg/ml)
for 16 h in LG and HG medium, with or without p53 inhibitor pifithrin-α (PFT-α) (30 μM) before being assayed for western blot analysis. Densitometric
values of LC3II/I/β-actin protein levels were quantified using the ImageJ software and normalized to control. One representative experiment is shown.
(b) HCT116 cells were transfected with ctr-siRNA and siDRAM and 36 h after transfection DRAM expression was assessed by RT-PCR analysis. One
representative experiment is shown. (c) HCT116 cells, transfected with ctr-siRNA and siDRAM, were kept in HG medium for 24 h and then
treated with ADR (2 μg/ml) for 16 h before the expression of p62 was measured by western blot analysis. Densitometric values of p62/β-actin protein
levels were quantified using the ImageJ software and normalized to control and the results are shown under the images. One representative
experiment is shown. Anti β-actin was used as protein loading control
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vitro results and underlined how the diabetic condition
might negatively influence tumor response to drugs by
impairing p53 pro-apoptotic activity.
Discussion
PUMA is a potent inducer of apoptosis, whereas inhibit-
ing PUMA curbs apoptosis associated with tissue injury
thus inducing therapeutic resistance [10, 11]. DRAM, by
itself or in conjunction with other factors downstream of
p53, can induce autophagy. Intriguingly, DRAM is also
involved in p53-induced cell death, although DRAM has
no detrimental effect on cell viability when expressed
alone [18, 19]. PUMA and DRAM are two p53 target
genes and it is well known that p53 after its activation
can select the final biological outcome depending on the
triggered transcriptional program [1, 2]. Indeed, although
p53 is better known for its proapoptotic activities, it can
also induce prosurvival effects, particularly under mild
stress conditions. Starting from our previous finding that
HG reduces p53 apoptotic activity [25, 26], we found here
that the HG condition changed the p53 response upon
ADR treatment, driving p53 transcriptional activity from
PUMA (death) to DRAM (autophagy) mutual antagonism
and that such interplay correlated with impaired drug-
induced cell death. Despite DRAM has been shown to in-
duce also autophagic cell death, in our system it played a
pro-survival role since silencing DRAM restored drug-
induced cell death inhibited by HG condition. We found
that DRAM expression increased the HG-induced au-
tophagy that, in turn, inhibited apoptosis and facili-
tated the resistance of tumor cells to anticancer
agents, in agreement with some studies [22, 23]. Fur-
ther studies will elucidate whether the PUMA to
DRAM differential expression is evident also in tumor
Fig. 4 Autophagy inhibition or DRAM silencing restored ADR-induced cell death in HG. (a) HCT116 cells were treated with ADR (2 μg/ml for 24 h) in
low (−) and high glucose (HG) condition with or without 25 μM CQ (for 16 h). After treatments, cells were in part fixed and stained with propidium
iodide (PI) for subG1 evaluation (upper panel) or lysed and analyzed by western immunoblotting to assess PARP cleavage (lower panel); relative quantification
of PARP cleavage/β-actin ratio is shown. One representative experiment is shown. Anti-β-actin was used as protein loading control. *P < 0.001. (b) RKO and
HCT116 cells, transfected with ctr-siRNA and siDRAM or left untransfected, were kept in low glucose (−) or high glucose (HG) medium for 24 h and then
treated with ADR (2 μg/ml) for 24 h before the percentage of dead cells was scored by trypan blue exclusion. The data are presented as
the means ± S.D. from three independent experiments. *P < 0.001. (c) RKO cells, transfected with ctr-siRNA and with siATG5 or left untransfected,
were kept in low glucose (−) or high glucose (HG) medium for 24 h and then treated with ADR (2 μg/ml) for 24 h before the percentage of dead cells
was scored by trypan blue exclusion. The data are presented as the means ± S.D. from three independent experiments. *P < 0.001
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tissues and whether it might be linked to tumor re-
sistance to drugs.
The PUMA to DRAM interplay was the result of p53
activation since blocking p53 transcriptional activity or
using p53 null cells abolished such expression. Given
that p53 can induce apoptosis in response to high geno-
toxic stress, it is plausible that HG might modify the
way through which p53 selectively induced gene tran-
scription. We know that p53 phosphorylation at serine
46 (Ser46) is a critical modification for induction of irre-
versible apoptosis and that inhibition of such phosphor-
ylation by HG contributes to chemoresistance and
reduction of p53-induced apoptosis [39, 40]. We also
know that mainly HIPK2 phosphorylates p53Ser46 and
that HG triggers HIPK2 degradation, impairing p53
apoptotic response [25, 41]. In agreement, we found that
PUMA expression is related to p53Ser46 modification
[25, 26]. However, although we found here mutual inter-
play between PUMA to DRAM transcription, whether
p53-induced DRAM expression depends on specific p53
modification (i.e., phosphorylation, acetylation, ect.) and/or
different extent of genotoxic stress, needs to be clarified.
DRAM is a lysosomal protein and a stress-induced
regulator of autophagy that was firstly discovered by
microarray analysis of mRNA species responsive to p53
Fig. 5 Autophagy inhibition or DRAM silencing restored ADR-induced
PUMA transcription in HG. (a) RKO and HCT116 cells were kept in low
glucose (LG) or high glucose (HG) medium for 24 h and then treated
with ADR (2 μg/ml) for 16 h in the presence or absence of 25 μM CQ,
before being assayed for semi-quantitative RT-PCR analysis of PUMA
gene expression. 28S was used as a control for efficiency of RNA
extraction and transcription. One representative experiment is
shown. (b) RKO and HCT116 cells, transfected with with siRNA
and siDRAM or untransfected, were kept in low glucose (−) or
high glucose (HG) medium for 24 h and then treated with ADR
(2 μg/ml) for 16 h before being assayed as in (a). One representative
experiment is shown. (c) Densitometric values of three independent
experiments as in (b) were quantified using the ImageJ software and
normalized to control. The values of control were set to 1. The data are
presented as fold of induction ± S.D. *P < 0.005
Fig. 6 Diabetes reduced the effect of chemotherapy that correlated
with increased DRAM and reduced PUMA gene expression, in vivo.
(a) Blood glucose concentration was evaluated in normoglycemic
(Normo) and streptozotocin (SZT)-treated mice (diabetic). Data are
presented as means ± S.D. *P < 0.005. (b) After mice reached a glucose
concentration exceeding 300 mg/dl (considered diabetic) upon SZT
treatment, solid tumors were obtained by injecting i.m. RKO cells on
the flank of each mouse. ADR treatment was performed when the
tumors became palpable. Ten days after ADR treatment, the size of
tumors showed statistical significant growth delay in normoglycemic
versus SZT mice. The data are presented as fold reduction ± S.D.
*P < 0.005. (c) Tumors measured in (b) were then explanted
from normoglycemic (Normo) and streptozotocin (SZT)-treated
mice and total mRNA was analysed by RT-PCR of PUMA and
DRAM gene expression. 28S was used as a control for efficiency
of RNA extraction and transcription. (c) Densitometric analysis of
gene expression in (b) was plotted as expression ratio to 28S. *P < 0.001
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and associated to autophagy induction [18], although the
effect of DRAM-mediated autophagy has not been clari-
fied until now. Starvation has been shown to activate the
PI3K/AKT pathway that inhibits apoptosis by DRAM-
mediated autophagy in hepatocellular cancer cells [42].
We can speculate that the loss of HIPK2/p53Ser46 phos-
phorylation in high glucose changes the p53 transcrip-
tional activation from pro-apoptotic (PUMA) gene
toward autophagy (DRAM) gene. Thus, DRAM silencing
restored the ADR-induced cell death in high glucose and
inhibited autophagy, highlighting a pro-survival effect of
DRAM, likely related to autophagy induction. Whether
this effect is cell specific or context–dependent needs
further studies.
Autophagy has been shown to have a pro-survival
effect in response to chemotherapy when for instance is
activated by endoplasmic reticulum stress or by reactive-
species oxygen (ROS) and to induce chemoresistance
[23, 43–46]. Our present studies show that blocking
autophagy with CQ or by depletion of ATG5 gene,
restored the ADR-dependent cell death, highlighting a
pro-survival effect of autophagy in this model. Interest-
ingly, blocking autophagy restored PUMA transcription.
This was somehow surprisingly. Preliminary findings
indicate that HIPK2 might be involved in PUMA to
DRAM interplay (data not shown). Further studies will
be needed to address whether HIPK2 might be degraded
also by autophagy other than by proteasome, as previ-
ously reported [47].
Conclusions
In conclusion, these findings uncover the antagonistic
role of PUMA and DRAM to govern drug-induced cell
death, highlighting how metabolic conditions such as
hyperglicemia might change p53 response to anticancer
therapies. These findings might be exploited to design
personalized therapies that combine the use of autoph-
agy inhibitors to improve the efficacy of chemotherapy
in hyperglicemic patients.
Abbreviations
ADR: Adriamycin; CQ: Chloroquine; DMEM: Dulbecco’s Modified Eagle’s medium;
DRAM: Damage-regulated autophagy modulator; FACS: Fluorescence Activated
Cell Sorting; FBS: Fetal bovine serum; HBSS: Hanks’ Balanced Salt solution;
HG: High glucose; LC3: Microtubule-associated protein light chain 3;
LG: Low glucose; PI: Propidium iodide; pifithrin-α: PFT-α; PUMA: p53
upregulated modulator of apoptosis; PVDF: polyvinylidene difluoride;
RT-PCR: reverse transcription polymerase chain reaction; SD: Standard
deviation; siRNA: small-interference RNA; STZ: Streptozotocin
Acknowledgements
This study was funded by the Italian Association for Cancer Research (AIRC)
Grant to GD (IG 2015 Id.16742) and by Ministry of Health (RF-2011-02347907)
to GT. We thank M. Granato, S. Soddu and A. Verdina for sharing reagents
and for critical discussion.
Authors‘contributions
GDO designed the study. AG, GP, SB, and GT performed experiments. GDO,
and MC analysed data. GDO wrote the paper. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Research, Advanced Diagnostics, and Technological Innovation,
Translational Research Area, Regina Elena National Cancer Institute, Rome, Italy.
2Department of Medical, Oral and Biotechnological Sciences, Tumor Biology
Section, University “G. d’Annunzio”, Via de Vestini, 31, 66013 Chieti, Italy.
3Department of Systems Medicine, University “Tor Vergata”, Rome, Italy.
4Department of Experimental Medicine, Institute Pasteur Cenci Bolognetti
Foundation, Sapienza University, Rome, Italy.
Received: 26 July 2017 Accepted: 5 September 2017
References
1. Carvajal LA, Manfredi JJ. Another fork in the road-life or death decisions by
the tumour suppressor p53. EMBO Rep. 2013;14:414–21.
2. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53.
Cell. 2009;137:413–31.
3. Muller PAJ, Vousden KH. P53 Mutations in cancer. Nat Cell Biol. 2013;15:2–8.
4. Weber JD, Zambetti GP. Renewing the debate over p53 apoptotic response.
Cell Death Diff. 2003;10:409–12.
5. Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, et al. Activation
of dendritic cells by tumor cell death. Oncoimmunology. 2012;1:1218–9.
6. Cirone M, Garufi A, Di Renzo L, Granato M, Faggioni A, D'Orazi G. Zinc
supplementation is requie for the cytotoxic and immunogenic effects
of chemotherapy in chemoresistant p53-functionally deficient cells.
Oncoimmunology. 2013;2:e26198.
7. Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D’Orazi G. Apoptosis as anticancer
mechanism: function and dysfunction of its modulators and targeted
therapeutic strategies. Aging-US. 2016;8:603–19.
8. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53.
Mol Cell. 2001;7:683–94.
9. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic
response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A. 2003;100:
1931–6.
10. Hikisz P, Kilianska ZM. PUMA, a critical mediator of cell death – one decade
on from its discovery. Cell Mol Biol Lett. 2012;17:646–69.
11. Yu J, Zhang L. PUMA a potent killer with or without p53. Oncogene. 2009;
27:S71–83.
12. Delbridge ARD, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer
therapy. Cell Death Diff. 2015;22:1071–80.
13. Rayan KM. p53 And autophagy in cancer: Guardian of the genome meets
guardian of the proteasome. Eur J Cancer. 2011;47:44–50.
14. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, et al.
Regulation of autophagy by cytoplasmic p53. Nat Cell Biol. 2008;10:676–87.
15. Scherz-Shouval R, Weidberg H, Gonen C, Wilder Z, Oren M. p53-Dependent
regulation of autophagy protein LC3 supports cancer cell survival under
prolonged starvation. Proc Natl Acad Sci U S A. 2010;107:18511–6.
16. Kenzelmann-Broz D, Spano Mello S, Bieging KT, Jiang D, Dusek RL, Brady CA, et
al. Global genomic profiling reveals an extensive p53-regulated autophagy
program contributing to key p53 responses. Genes Dev. 2013;27:1016–31.
17. Jing K, Song KS, Shin S, Kim N, Jeong S, Oh HR, et al. Docosahexaenoic acid
induces autophagy through p53/AMPK/mTOR signaling and promotes
apoptosis in human cancer cells harboring wild-type p53. Autophagy.
2011;7:1348–58.
18. Crighton D, Wilkinson S, O’Prey J, Syed N, Smith P, Harrison PR, et al. DRAM,
a p53- induced modulator of autophagy, is critical for apoptosis. Cell. 2006;
126:121–34.
19. Crighton D, Wilkinson S, Ryan KM. DRAM links autophagy to p53 programmed
cell death. Autophagy. 2007;3:72–4.
Garufi et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:126 Page 9 of 10
20. Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA, Kroemer G. Autophagy
regulation by p53. Curr Opin Cell Biol. 2010;22:181–5.
21. Green DR, Levine B. To be or not to be? How selective autophagy and cell
death govern cell fate. Cell. 2014;157:65–75.
22. Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N,
et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol. 2005;
25:1025.1040.
23. Huang Z, Zhou L, Chen Z, Nice EC, Huang C. Stress management by autophagy:
implications for chemoresistance. Int J Cancer. 2016;139:23–32.
24. Marino G, Niso-Santano M, Baehrecke EH, Kroemer G. Self consumption: the
interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol. 2014;15:81–94.
25. Garufi A, D'Orazi G. High glucose dephosphorylates serine 46 and inhibits
p53 apoptotic activity. J Exp Clin Cancer Res. 2014;33:79.
26. Baldari S, Garufi A, Granato M, Pistritto G, Cirone M, D’Orazi G. Hyperglycemia
triggers HIPK2 protein degradation. Oncotarget. 2017;8:1190–203.
27. Biernacka KM, Uzoh CC, Zeng L, Persad RA, Bahl A, Gillatt D, et al. Hyperglicaemia-
induced chemoresistance of prostate cancer cells due to IGFBP2. Endocr Relat
Cancer. 2013;20:741–51.
28. Ma YS, Yang IP, Tsai HL, Huang CW, Juo SH, Wang JY. High glucose modulates
antiproliferative effect and citotoxicity of 5-fluorouracil in human colon cancer
cells. DNA Cell Biol. 2014;33:64–72.
29. Michihara A, Toda K, Kubo T, Fujiwara Y, Akasaki K, Tsuji H. Disruptive effect
of choroquine on lysosomes in cultured rat hepatocytes. Biol Pharm Bull.
2005;28:947–51.
30. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS,
Chernov MV, et al. A chemical inhibitor of p53 that protects mice from
the side effects of cancer therapy. Science. 1999;285:1733–7.
31. Garufi A, Trisciuoglio D, Porru M, Leonetti C, Stoppacciaro A, D’Orazi V, et al.
A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and
R273H) p53 in cancer cells. J Exp Clin Cancer Res. 2013;32:72.
32. Garufi A, Ricci A, Iorio E, Carpinelli G, Pistritto G, Cirone M, et al. Glucose
restriction induces cell death in parental but not in HIPK2 depleted RKO
colon cancer cells: molecular mechanisms and implications for tumor
therapy. Cell Death Disease. 2013;4:e639.
33. Graham ML, Janecek JL, Kittredge JA, Hering BJ, Schuurman HJ. The streptozotocin-
induced diabetic nude mouse model: differences between animals from different
sources. Comp Med. 2011;61:356–60.
34. Crighton D, O’Perey J, Bell HS, Ryan KM. p73 Regulates DRAM-independent
autophagy that does not contribute to programmed cell death. Cell Death
Diff. 2007;14:1071–9.
35. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Hagai Abeliovich H, Arozena AA,
et al. Guidelines for the use and interpretation of assays for monitoring
autophagy (2nd edition). Autophagy. 2016;12:1–222.
36. Mizushima N, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagosome
formation. Annu Rev Cell Dev Biol. 2011;27:107–32.
37. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, et al. Reversible
dysfunction of wild-type p53 following homeodomain-interacting protein kinase-
2 knockdown. Cancer Res. 2008;15:3707–14.
38. Garufi A, Ubertini V, Mancini F, D’Orazi V, Baldari S, Moretti F, et al. The
beneficial effect of zinc(II) on low-dose chemotherapeutic sensitivity involves
p53 activation in wild-type p53 cancer cells. J Exp Clin Cancer Res. 2015;34:87.
39. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, et al. P53AIP1,
A potential mediator of p53-dependent apoptosis, and its regulation by
Ser-46-phosphorylated p53. Cell. 2000;102:849–62.
40. Ichwan SJA, Yamada S, Sumreijkanchanakij P, Ibrahim-Auerkari E, Eto K, Ikeda MA.
Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53
resistance in oral squamous cell carcinoma cells. Oncogene. 2006;25:1216–24.
41. D’Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, et al.
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser46
and mediates apoptosis. Nat Cell Biol. 2002;4:11–9.
42. Liu K, Shi Y, Guo XH, Ouyang YB, Wang SS, Liu DJ, et al. Phoaphorylated AKT
inhibits the apoptosis induced by DRAM-mediated mitophagy in hepatocellular
carcinoma by preventing the translocation of DRAM to mitochondria. Cell Death
Dis. 2014;5:e1078.
43. Granato M, Santarelli R, Lotti LV, Di Renzo L, Gonnella R, Garufi A, et al. JNK
and macroautophagy activation by bortezomib has a pro-survival effect in
primary effusion lymphoma cells. PLoS One. 2013;8:e75965.
44. Yan YL, Xu ZJ, Dai S, Qian L, Sun LQ, Gong ZC. Targeting autophagy to sensitive
glioma to temozolomide treatment. J Exp Clin Cancer Res. 2016;35:23.
45. Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liaison
in cancer cells. Cell Death Dis. 2016;7:e2253.
46. Galadari S, Rahman A, Pallichankandy S, Thayyullathil F. Reactive oxygen
species and cancer paradox: to promore or to suppress? Free Radic Biol
Med. 2017;104:144–64.
47. Nardinocchi L, Puca R, Givol D, D’Orazi G. HIPK2-A therapeutical target to be
(re)activated for tumor suppression: role in p53 activation and HIF-1alpha
inhibition. Cell Cycle. 2010;9:1–6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Garufi et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:126 Page 10 of 10
